Hippo通路对体外骨髓间充质干细胞分化、增殖与迁移的影响
该研究为体外实验,使用C57BL/6小鼠骨髓间充质干细胞(BMSCs),经荧光激活细胞分选鉴定并评估成骨、成软骨、成脂分化能力。通过与小鼠肺上皮细胞(MLE-12)及小气道上皮细胞生长培养基(SAGM)间接共培养诱导BMSCs向II型肺泡上皮细胞(AEC II)分化。用2-脱氧-D-葡萄糖(2-DG)和9E1调控Hippo通路,检测表面蛋白SPB、SPC、SPD mRNA及pro-SPC蛋白表达、增殖率、划痕愈合及Transwell迁移。结果显示2-DG以剂量依赖方式激活Hippo通路,5 mmol/L时促进分化和增殖效果最大;9E1抑制Hippo通路可逆转上述效应。
要点
- 2-DG以剂量依赖方式激活Hippo通路,5 mmol/L时促分化与增殖效果最大。
- 5 mmol/L 2-DG组SPC mRNA(2-ΔΔCT)8.06±0.68 vs 对照6.59±0.79,pro-SPC/β-actin 5.80±1.86 vs 4.93±1.18,均P<0.05。
- 5 mmol/L 2-DG组增殖率(145.46±18.18)% vs 对照(98.91±4.36)%,P<0.05。
- 9E1抑制Hippo通路可逆转2-DG效应:增殖率(80.00±7.27)% vs 对照(98.91±4.36)%,P<0.05。
- 2-DG激活Hippo通路后划痕愈合(27.17±3.53)% vs 对照(52.45±6.52)%、向ARDS肺组织条件培养基归巢细胞数(倍数,相对对照)2.77±0.21 vs 1.90±0.19,均P<0.05。
适用人群与场景
- 体外培养的C57BL/6小鼠骨髓间充质干细胞(BMSCs),经荧光激活细胞分选鉴定并具成骨、成软骨、成脂分化能力。
- BMSCs与小鼠肺上皮细胞(MLE-12)及小气道上皮细胞生长培养基(SAGM)间接共培养诱导向II型肺泡上皮细胞(AEC II)分化。
- 迁移实验使用急性呼吸窘迫综合征(ARDS)肺组织条件培养基。
处置流程与药物剂量
- 用2-脱氧-D-葡萄糖(2-DG)激活Hippo通路,增殖实验干预浓度为0.1、0.5、1.0、5.0 mmol/L。
- 用9E1抑制Hippo通路,可逆转2-DG的促分化、促增殖和促迁移效应。
- 分化评估检测BMSCs表面蛋白SPB、SPC、SPD mRNA(qRT-PCR)及pro-SPC蛋白(Western Blot)。
- 增殖评估采用甲基噻唑基四唑(MTT)法;迁移评估采用划痕实验和Transwell小室实验。
研究设计与关键结果
- 2-DG以剂量依赖方式激活Hippo通路,5 mmol/L时促分化与增殖效果最大:SPB mRNA(2-ΔΔCT)2.42±0.28 vs 1.89±0.11,SPC mRNA 8.06±0.68 vs 6.59±0.79,SPD mRNA 6.45±0.37 vs 5.27±0.28,pro-SPC/β-actin 5.80±1.86 vs 4.93±1.18,增殖率(145.46±18.18)% vs(98.91±4.36)%,均P<0.05。
- 9E1抑制Hippo通路可逆转上述效应:SPB mRNA(2-ΔΔCT)1.32±0.17 vs 1.89±0.11,SPC mRNA 3.91±0.34 vs 6.59±0.79,SPD mRNA 3.38±0.25 vs 5.27±0.28,pro-SPC/β-actin 2.48±0.17 vs 4.93±1.18,增殖率(80.00±7.27)% vs(98.91±4.36)%,均P<0.05。
- 2-DG激活Hippo通路后水平迁移能力增强:划痕愈合(27.17±3.53)% vs(52.45±6.52)%,P<0.05;向ARDS肺组织条件培养基归巢细胞数(倍数,相对对照)2.77±0.21 vs 1.90±0.19,P<0.05。
- 9E1抑制Hippo通路后上述迁移效应被逆转:划痕愈合(79.89±8.42)% vs(52.45±6.52)%,归巢细胞数(倍数,相对对照)1.69±0.13 vs 1.90±0.19,均P<0.05。
证据类型、等级与局限
- 证据类型:体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出临床推荐;体外实验显示激活Hippo通路可增强BMSCs向AEC II分化、增殖及向ARDS肺组织条件培养基迁移归巢。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the effects of Hippo pathway on differentiation, proliferation, and migration of bone marrow mesenchymal stem cells (BMSCs) in vitro.
METHODS: BMSCs of C57BL/6 mice were identified using fluorescence-activated cellsorting analysis and the capabilities of osteogenic, chondrogenic and adipogenic differentiation were evaluated. The differentiation of BMSCs to type II alveolar epithelial cells (AEC II) was induced by indirect co-culture with mouse lung epithelial cells (MLE-12) and small airway epithelial cell growth medium (SAGM). The Hippo pathway was regulated by 2-deoxy-D-glucose (2-DG) and 9E1, the effects of 2-DG and 9E1 on the expression of BMSCs surface proteins (SPB, SPC and SPD) mRNA and pro-SPC protein were detected by real time quantitative polymerase chain reaction (qRT-PCR) and Western Blot. The effect of Hippo pathway on differentiation of BMSCs to AEC II cells was evaluated. The effect of Hippo pathway on the proliferation of BMSCs was evaluated by methyl thiazolyl tetrazolium (MTT) assay (intervention of 0.1, 0.5, 1.0, 5.0 mmol/L 2-DG). The scratch test and Transwell chamber test were used to analyze the effect of Hippo pathway on migration ability of BMSCs to conditioned medium of acute respiratory distress syndrome (ARDS) lung tissue.
RESULTS: 2-DG could activate Hippo pathway in a dose-dependent manner and promote the differentiation to AEC II and proliferation of BMSCs, the maximum effects were observed after 5 mmol/L of 2-DG treatment [SPB mRNA (2-ΔΔCT): 2.42±0.28 vs. 1.89±0.11, SPC mRNA (2-ΔΔCT): 8.06±0.68 vs. 6.59±0.79, SPD mRNA (2-ΔΔCT): 6.45±0.37 vs. 5.27±0.28, pro-SPC/β-actin: 5.80±1.86 vs. 4.93±1.18, proliferation rate: (145.46±18.18)% vs. (98.91±4.36)%, all P < 0.05], but 9E1 could reverse those effects through inhibition of Hippo pathway [SPB mRNA (2-ΔΔCT): 1.32±0.17 vs. 1.89±0.11, SPC mRNA (2-ΔΔCT): 3.91±0.34 vs. 6.59±0.79, SPD mRNA (2-ΔΔCT): 3.38±0.25 vs. 5.27±0.28, pro-SPC/β-actin: 2.48±0.17 vs. 4.93±1.18, proliferation rate: (80.00±7.27)% vs. (98.91±4.36)%, all P < 0.05]. The ability of horizontal migration [wound healing: (27.17±3.53)% vs. (52.45±6.52)%, P < 0.05] and homing BMSCs to conditioned medium of ARDS lung tissue [cell count (fold, relative to control): 2.77±0.21 vs. 1.90±0.19, P < 0.05] were increased after activation of Hippo pathway by 2-DG treatment, but those effects were reversed after inhibition of Hippo pathway by 9E1 treatment [wound healing: (79.89±8.42)% vs. (52.45±6.52)%, cell count (fold, relative to control): 1.69±0.13 vs. 1.90±0.19, both P < 0.05].
CONCLUSIONS: Activation of Hippo pathway could enhance differentiation of BMSCs to AEC II, promote proliferation and ability of horizontal migration and homing BMSCs to conditioned medium of ARDS lung tissue in vitro.
参考来源
- Li L, Dong L, Chen Y, et al. [Effects of Hippo pathway on differentiation, proliferation, migration of bone marrow mesenchymal stem cells in vitro]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31315736. doi:10.3760/cma.j.issn.2095-4352.2019.06.018
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。